Beloqui A - Search Results

1

Surface Modification of Lipid-Based Nanoparticles.

Xu Y, Fourniols T, Labrak Y, Préat V, Beloqui A, des Rieux A. Xu Y, et al. Among authors: beloqui a. ACS Nano. 2022 May 24;16(5):7168-7196. doi: 10.1021/acsnano.2c02347. Epub 2022 Apr 21. ACS Nano. 2022. PMID: 35446546 Review.

2

Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.

Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A, des Rieux A, Préat V. Beloqui A, et al. J Control Release. 2013 Mar 10;166(2):115-23. doi: 10.1016/j.jconrel.2012.12.021. Epub 2012 Dec 22. J Control Release. 2013. PMID: 23266764

3

Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs.

Beloqui A, Solinís MÁ, des Rieux A, Préat V, Rodríguez-Gascón A. Beloqui A, et al. Int J Pharm. 2014 Jul 1;468(1-2):105-11. doi: 10.1016/j.ijpharm.2014.04.027. Epub 2014 Apr 16. Int J Pharm. 2014. PMID: 24746410

4

pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.

Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Préat V. Beloqui A, et al. Int J Pharm. 2014 Oct 1;473(1-2):203-12. doi: 10.1016/j.ijpharm.2014.07.009. Epub 2014 Jul 8. Int J Pharm. 2014. PMID: 25014369

5

Nanostructured lipid carriers: Promising drug delivery systems for future clinics.

Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Beloqui A, et al. Nanomedicine. 2016 Jan;12(1):143-61. doi: 10.1016/j.nano.2015.09.004. Epub 2015 Sep 26. Nanomedicine. 2016. PMID: 26410277 Review.

6

Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles.

Bouttefeux O, Beloqui A, Preat V. Bouttefeux O, et al. Among authors: beloqui a. Curr Pharm Des. 2016;22(9):1161-76. doi: 10.2174/1381612822666151216150238. Curr Pharm Des. 2016. PMID: 26675223 Review.

7

Nanoparticle transport across in vitro olfactory cell monolayers.

Gartziandia O, Egusquiaguirre SP, Bianco J, Pedraz JL, Igartua M, Hernandez RM, Préat V, Beloqui A. Gartziandia O, et al. Among authors: beloqui a. Int J Pharm. 2016 Feb 29;499(1-2):81-89. doi: 10.1016/j.ijpharm.2015.12.046. Epub 2015 Dec 22. Int J Pharm. 2016. PMID: 26721725

8

Reformulating cyclosporine A (CsA): More than just a life cycle management strategy.

Guada M, Beloqui A, Kumar MN, Préat V, Dios-Viéitez Mdel C, Blanco-Prieto MJ. Guada M, et al. Among authors: beloqui a. J Control Release. 2016 Mar 10;225:269-82. doi: 10.1016/j.jconrel.2016.01.056. Epub 2016 Jan 30. J Control Release. 2016. PMID: 26829101 Review.

9

Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs.

Beloqui A, Coco R, Préat V. Beloqui A, et al. Curr Pharm Des. 2016;22(40):6192-6206. doi: 10.2174/1381612822666160211141813. Curr Pharm Des. 2016. PMID: 26864312 Review.

10

Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease.

Guada M, Beloqui A, Alhouayek M, Muccioli GG, Dios-Viéitez Mdel C, Préat V, Blanco-Prieto MJ. Guada M, et al. Among authors: beloqui a. Int J Pharm. 2016 Apr 30;503(1-2):196-8. doi: 10.1016/j.ijpharm.2016.03.012. Epub 2016 Mar 10. Int J Pharm. 2016. PMID: 26972380

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85 results

Search Page